Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. - Concepedia

Concepedia

Publication | Closed Access

Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.

34

Citations

22

References

2004

Year

Wolfgang J. Köstler, Günther Steger, Afschin Soleiman, Barbara Schwab, Christian F. Singer, Sandra Tomek, Thomas Brodowicz, Michael Krainer, Christoph Wiltschke, Reinhard Horvat,

Abstract

Serial monitoring of serum Her-2/neu ECD levels may represent a valuable tool to predict pathological response to trastuzumab-based neoadjuvant therapy in patients with Her-2/neu-overexpressing tumors.

References

	Year	Citations

Page 1